AU2012264951A1 - Radiolabelled glutaminyl cyclase inhibitors - Google Patents

Radiolabelled glutaminyl cyclase inhibitors Download PDF

Info

Publication number
AU2012264951A1
AU2012264951A1 AU2012264951A AU2012264951A AU2012264951A1 AU 2012264951 A1 AU2012264951 A1 AU 2012264951A1 AU 2012264951 A AU2012264951 A AU 2012264951A AU 2012264951 A AU2012264951 A AU 2012264951A AU 2012264951 A1 AU2012264951 A1 AU 2012264951A1
Authority
AU
Australia
Prior art keywords
alkyl
substituted
cycloalkyl
phenyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012264951A
Other languages
English (en)
Inventor
Hans-Ulrich Demuth
Ulrich Heiser
Daniel Ramsbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivoryon Therapeutics AG
Original Assignee
Probiodrug AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug AG filed Critical Probiodrug AG
Publication of AU2012264951A1 publication Critical patent/AU2012264951A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012264951A 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors Abandoned AU2012264951A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490654P 2011-05-27 2011-05-27
US61/490,654 2011-05-27
PCT/EP2012/059649 WO2012163773A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Publications (1)

Publication Number Publication Date
AU2012264951A1 true AU2012264951A1 (en) 2013-12-12

Family

ID=46149465

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012264951A Abandoned AU2012264951A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Country Status (14)

Country Link
US (2) US8945510B2 (enExample)
EP (1) EP2714098A1 (enExample)
JP (1) JP2014515364A (enExample)
KR (1) KR20140028076A (enExample)
CN (1) CN103561776B (enExample)
AU (1) AU2012264951A1 (enExample)
BR (1) BR112013030341A2 (enExample)
CA (1) CA2835014A1 (enExample)
EA (1) EA028533B1 (enExample)
IL (1) IL229187A (enExample)
MX (1) MX2013013946A (enExample)
SG (2) SG194770A1 (enExample)
WO (1) WO2012163773A1 (enExample)
ZA (1) ZA201308329B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6454651B2 (ja) 2013-03-15 2019-01-23 プロビオドルグ エージー 新規阻害剤
CN104230778B (zh) * 2014-07-14 2017-01-04 大连大学 β-烃氧酰基-γ-烃基-N-烃基-γ-丁内酰胺的合成方法
CR20170076A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
KR102230832B1 (ko) * 2019-06-17 2021-03-24 (주) 메디프론디비티 N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물
AU2020408107B2 (en) 2019-12-20 2026-04-23 Nuevolution A/S Compounds active towards nuclear receptors
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1250834B (enExample) 1963-01-09
US5304367A (en) * 1990-11-16 1994-04-19 New York University In vivo brain imaging agent and method for diagnosis of psychiatric disorders
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
EP2021340B1 (en) 2006-04-21 2014-07-23 The Government Of The United States, As Represented by The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US8278345B2 (en) * 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5677297B2 (ja) * 2008-07-31 2015-02-25 プロビオドルグ エージー 神経変性疾患の診断／予後判定の指標としてのグルタミニルシクラーゼ
SG193828A1 (en) 2008-09-04 2013-10-30 Probiodrug Ag Novel inhibitors
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
US8269019B2 (en) * 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors

Also Published As

Publication number Publication date
KR20140028076A (ko) 2014-03-07
EP2714098A1 (en) 2014-04-09
CN103561776A (zh) 2014-02-05
BR112013030341A2 (pt) 2016-11-29
SG10201604304RA (en) 2016-07-28
MX2013013946A (es) 2014-01-31
IL229187A (en) 2017-04-30
ZA201308329B (en) 2015-02-25
US9610368B2 (en) 2017-04-04
CN103561776B (zh) 2016-08-31
CA2835014A1 (en) 2012-12-06
WO2012163773A1 (en) 2012-12-06
NZ617581A (en) 2016-03-31
US20120301398A1 (en) 2012-11-29
SG194770A1 (en) 2013-12-30
EA028533B1 (ru) 2017-11-30
US20150104389A1 (en) 2015-04-16
EA201301334A1 (ru) 2014-05-30
IL229187A0 (en) 2013-12-31
JP2014515364A (ja) 2014-06-30
US8945510B2 (en) 2015-02-03

Similar Documents

Publication Publication Date Title
US9610368B2 (en) Radiolabelled glutaminyl cyclase (QC) inhibitors and uses of same
EP2501696B1 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
EP3143011B1 (en) Deuterated heterocyclic compounds and their use as imaging agents
CA3097685C (en) 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative compound for directly inhibiting asm activity, and use thereof
KR101639268B1 (ko) １８ ｆ-표지된 폴레이트
KR101636245B1 (ko) 신규한 [ｆ-１８]-표지된 ｌ-글루탐산- 및 ｌ-글루타민 유도체 (ｉ), 그의 용도 및 그의 제조 방법
AU2017200934A1 (en) Compositions, methods, and systems for the synthesis and use of imaging agents
JP2011529086A (ja) Ａｄ病変を同定するために有用な造影剤
JP5322180B2 (ja) フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
TW201026336A (en) Benzothiazole amides for detection of amyloid beta
Luo et al. Synthesis and preclinical evaluation of 11C-labeled 7-Oxo-2, 4, 5, 7-tetrahydro-6H-pyrazolo [3, 4-c] pyridine radioligands for RIPK1 positron emission tomography imaging
TW201023900A (en) Radioisotope-labeled lysine and ornithine derivatives, their use and processes for their preparation
SagsttaS'Transversa Heiser et al.(43) Pub. Date: Nov. 29, 2012
NZ617581B2 (en) Radiolabelled glutaminyl cyclase inhibitors
US20110217234A1 (en) Imaging ligands
HK1194301B (en) Radiolabelled glutaminyl cyclase inhibitors
HK1194301A (en) Radiolabelled glutaminyl cyclase inhibitors
EP3845541A1 (en) Radioactive imidazothiadiazole derivative compound
US20260027242A1 (en) Pet radioligands for imaging glutaminyl cyclase activity
CN121443582A (zh) 用于诊断、治疗和/或预防癌症的取代的2-苯基哌啶化合物
WO2025225738A1 (ja) がん治療用医薬組成物
JP2021102593A (ja) タウを画像化する新規化合物
Imai et al. Development of a Novel Methylated Pet Tracer Designed to Enhance the Photostability of Pm-Pbb3
WO2011124713A1 (en) Labelled huprine derivatives and their use in medical imaging
JP2010202584A (ja) テクネチウム標識化合物含有診断用組成物

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted